First Therapeutic Approval in 16 years for MPM

FDA Perspectives on the Use of Liquid Biopsy in NSCLC

Funding Opportunities for Innovative Multidisciplinary Cancer Research Teams

FDA Approves Pralsetinib for RET Fusion–Positive NSCLC

Huge Strides for Liquid Biopsy Assays with Two FDA Approvals

Dr. Harpreet Singh Discusses the Conduct of FDA Clinical Trials During the COVID-19 Pandemic

The Chen-Huang Center for EGFR-Mutant Lung Cancers Represents a ‘Concentrated and Focused Effort’ in Studying Th is Disease Subset

Anne-Marie Baird, BSc, PhD

Oncology Trials Could Benefit From Increased Data on Tobacco Use

Paul G. Kluetz, MD

Shirish Gadgeel, MD

Karen L. Reckamp, MD, MS